Janux Therapeutics' lead program, JANX007, shows promising early results in prostate cancer, with significant PSA declines and no serious side effects reported. The company's strong financial position ...
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary ...
Janux to host virtual investor event today at 4:30 PM Eastern Time “These clinical data show substantial activity with JANX007 in 5L metastatic castration-resistant prostate cancer patients and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback